Lipopeptide compounds for the treatment of pain disorders
US11912645B2 · kind B2 · utility
Assignees
- INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
- CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE
- UNIVERSITE PAUL SABATIER—TOULOUSE III
- INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION L'ENVIRONNEMENT
- Universite De Montpellier
- Ecole Nationale Supérieure de Chimie de Montpellier
Inventors
Key dates
| Filing date | Apr 27, 2018 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Feb 27, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.